Log In
Print
BCIQ
Print
Print this Print this
 

Adagen, adenosine deaminase (PEG-adenosine deaminase)

  Manage Alerts
Collapse Summary General Information
Company Sigma-Tau Group
DescriptionPegylated adenosine deaminase
Molecular Target Not available
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentMarketed
Standard IndicationImmunodeficiency
Indication DetailsTreat severe combined immunodeficiency disease (SCID)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$654.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today